Skip to main content

Kummerfeld Keith C's Form 4 filing

Arcturus Therapeutics Holdings Inc.ARCT · filed Jul 18, 2023

Accession no.
0001193805-23-001002
Filed
Jul 18, 2023
Trade date
Jul 14, 2023
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market sales total $243.9K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Kummerfeld Keith CCIK 0001762749Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 14, 2023Common StockMOption exerciseAcquired+4,500$9.04+$40,6805,450Direct
Jul 14, 2023Common StockMOption exerciseAcquired+1,437$4.99+$7,170.636,887Direct
Jul 14, 2023Common StockMOption exerciseAcquired+1,031$14.12+$14,557.727,918Direct
Jul 14, 2023Common StockSSaleDisposed−6,968$35.00F2−$243,880950Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jul 14, 2023Common StockMOption exerciseDisposed−4,500$0.00$021,000Direct
Jul 14, 2023Common StockMOption exerciseDisposed−1,437$0.00$07,126Direct
Jul 14, 2023Common StockMOption exerciseDisposed−1,031$0.00$07,938Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

These shares were sold in multiple transactions, each at a price of $35.00 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by it on July 14, 2023.

Referenced by the price of 1 transaction in Table I.

Remarks

Senior Vice President of Finance (Principal Accounting Officer)

Read the full filing on SEC EDGAR (opens in a new tab)